Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
-
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas
-
Landmark regulatory milestone makes the River stent available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy Serenity Medical...
-
Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
-
Name chosen for AVERSA Fentanyl commercial product
-
New York, March 30, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates today’s announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose...
-
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...
-
MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
-
NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
-
- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics,...